Caribou Biosciences Inc. (CRBU)
CRBU trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/0001619856-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CRBU on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001619856 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $11.2M |
| Net income | -$148.1M |
| Operating income | -$148.3M |
| Net margin | -1327.4% |
| Operating margin | -1329.4% |
| Revenue growth | +11.7% |
| Cash | $12.4M |
| Total assets | $175.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $26.1M cash; operating cash flow -$23.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 108,036,729 (2026-11-02); 93,468,038 a year earlier; 88,431,136 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $34K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.6M | -$26.6M | -$22.5M | $26.1M | No debt tags | $9.4M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $1.5M | -$24.3M | -$22.8M | $26.2M | No debt tags | $10.0M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $2.4M | -$25.1M | -$27.0M | $12.1M | No debt tags | $11.2M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $3.9M | -$26.5M | -$20.8M | $12.4M | No debt tags | $11.2M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $2.2M | -$27.5M | -$25.2M | $11.1M | No debt tags | $9.3M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $2.7M | -$54.1M | -$28.3M | $25.2M | No debt tags | $9.1M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $2.4M | -$40.0M | -$36.7M | $29.4M | No debt tags | $9.9M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $2.1M | -$35.5M | -$35.5M | $16.3M | No debt tags | $10.0M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-05-08 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-06-05 |
Source: SEC EDGAR submissions feed, 326 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -19.4% |
| 1 month | -23.0% |
| 3 months | -77.5% |
| Year to date | -77.2% |
| 1 year | -81.8% |
| From 52-week high | -85.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TIL | Instil Bio Inc. | $5.75 | -5.43% | $39.0M |
| EXOZ | eXoZymes Inc. | $3.99 | +4.18% | $37.1M |
| ELUT | Elutia Inc. | $0.8229 | +0.35% | $36.5M |
| IMA | ImageneBio Inc. | $3.20 | -7.78% | $39.9M |
| KLRS | Kalaris Therapeutics Inc. | $1.46 | -7.30% | $34.8M |
| LONA | LeonaBio Inc. | $3.23 | -6.92% | $30.4M |
| INKT | MiNK Therapeutics Inc. | $9.35 | +0.11% | $48.0M |
| INMB | INmune Bio Inc. | $0.9464 | -9.87% | $29.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier